| Title |
Extraordinary and prolonged Erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report
|
|---|---|
| Published in |
International Medical Case Reports Journal, May 2017
|
| DOI | 10.2147/imcrj.s134944 |
| Pubmed ID | |
| Authors |
Elisabetta Gambale, Consiglia Carella, Paolo Amerio, Fiamma Buttitta, Rosa Lucia Patea, Clara Natoli, Michele De Tursi |
| Abstract |
Several small molecules, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib, have been demonstrated to significantly improve clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but erlotinib activity in EGFR wild-type squamous carcinoma is still highly debated. Here, we describe a prolonged and unexpected clinical response to erlotinib in a male former heavy cigarette smoker with wild-type EGFR squamous-cell cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 9 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor | 2 | 22% |
| Other | 2 | 22% |
| Researcher | 1 | 11% |
| Student > Ph. D. Student | 1 | 11% |
| Unknown | 3 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 44% |
| Biochemistry, Genetics and Molecular Biology | 1 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 11% |
| Unknown | 3 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 May 2017.
All research outputs
#15,460,734
of 22,974,684 outputs
Outputs from International Medical Case Reports Journal
#168
of 375 outputs
Outputs of similar age
#194,782
of 310,769 outputs
Outputs of similar age from International Medical Case Reports Journal
#6
of 7 outputs
Altmetric has tracked 22,974,684 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 375 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,769 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one.